BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26162577)

  • 21. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraindividual comparison of
    Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
    Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
    Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
    Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
    Wong KK; Cahill JM; Frey KA; Avram AM
    Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
    J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
    Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
    Jindal T; Kumar A; Venkitaraman B; Dutta R; Kumar R
    Korean J Intern Med; 2010 Dec; 25(4):386-91. PubMed ID: 21179276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
    Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R
    Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
    Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of metastases outside the liver and abdominal lymph nodes on
    Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
    J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
    Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
    Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.